A multiple-dose pharmacokinetic interaction study between didanosine (Videx®) and ciprofloxacin (Cipro®) in male subjects seropositive for HIV but asymptomatic

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 1, 1997, Pages 65-77

  Knupp, Catherine A ^a   Barbhaiya, Rashmi H ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

ciprofloxacin; ddI; didanosine; drug interaction; Videx

Indexed keywords

CIPROFLOXACIN; DIDANOSINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIPROFLOXACIN; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; RANDOM ALLOCATION;

EID: 0031029036     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199701)18:1<65::AID-BDD13>3.0.CO;2-R     Document Type: Article

References (29)

1. H. Mitsuya and S. Broder, Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Nat. Acad. Sci. USA, 83, 1911 (1986).
2. C. A. Knupp, W. C. Shyu, R. Dolin, F. T. Valentine, C. McLaren, R. R. Martin, K. A. Pittman and R. H. Barbhaiya, Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin. Pharmacol. Ther., 49, 523-535 (1991).
3. N. R. Hartman, R. Yarchoan, J. M. Pluda, R. V. Thomas, K. S. Marczyk, S. Broder and D. G. Johns, Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin. Pharmacol. Ther., 47, 647-654 (1990).
4. C. A. Knupp, W. C. Shyu, E. A. Morgenthien, J. S. Lee and R. H. Barbhaiya, Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog. Pharm. Res., 10, 1157-1164 (1993).
5. B. D. Anderson, M. B. Wygant, T. X. Xiang, W. A. Waugh and V. J. Stella, Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleosides: potential anti-AIDS agents. Int. J. Pharm., 45, 27-37 (1988).
6. M. LeBel, Ciprofloxacin: Chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy, 8, 3-33 (1988).
7. F. DeLalla, R. Maserati, P. Scarpellini, P. Marone, R. Nicolin, F. Caccamo and R. Rigoli, Clarithromycin-ciprofloxacin-amikacin for therapy of Mycobacterium avium-Mycobacterium intracellulare bacteremia in patients with AIDS. Antimicrob. Agents Chemother., 36, 1567-1569 (1992).
8. L. S. Young, O. G. W. Berlin and C. B. Inderlied, Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria. Am. J. Med., 82 (suppl. 4A), 23-26 (1987).
9. M. Sarkar, R. E. Polk, P. S. Guzelian, C. Hunt and H. T. Karnes, In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes. Antimicrob. Agents Chemother., 34, 594-599 (1990).
10. D. P. Healy, R. E. Polk, L. Kanawati, D. T. Rock and M. L. Mooney, Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob. Agents Chemother., 33, 474-478 (1989).
11. H. Lode, Drug interactions with quinolones. Rev. Infect. Dis., 10 (suppl. 1), S132-S136 (1988).
12. R. W. Frost, K. C. Lasseter, A. J. Noe, E. C. Shamblen and J. T. Lettieri, Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob. Agents Chemother., 36, 830-832 (1992).
13. D. E. Nix, W. A. Watson, M. E. Lener, R. W. Frost, G. Krol, H. Goldstein, J. T. Lettieri and J. J. Schentag, Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin. Pharmacol. Ther., 46, 700-705 (1989).
14. J. Sahai, K. Gallicano, L. Oliveras, S. Khaliq, N. Hawley-Foss and G. Garber, Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin. Pharmacol. Ther., 53, 292-297 (1993).
15. C. A. Knupp, F. A. Stancato, E. E. Papp and R. H. Barbhaiya, Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography. J. Chromatogr., 533, 282-290 (1990).
16. D. E. Nix, J. M. De Vito and J. J. Schentag, Liquid chromatographic determination of ciprofloxacin in serum and urine. Clin. Chem., 31, 684-686 (1985).
17. P. Prescott, An approximate test for outliers in linear models. Technometrics, 17, 129-132 (1975).
18. M. Gibaldi and D. Perrier, Pharmacokinetics, 2nd edn, Dekker, New York, 1982.
19. S. Riegelman and P. Collier, The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J. Pharmacokinet. Biopharm., 8, 509-534 (1980).
20. B. J. Winer, Statistical Principles in Experimental Design, 2nd edn, McGraw-Hill, New York, 1971.
21. W. J. Conover and R. L. Iman, Rank transformations as a bridge between parametric and nonparametric statistics. Am. Statistician, 35, 124-133 (1981).
22. J. L. Gill, Design and Analysis of Experiments in the Animal and Medical Sciences, Vol. 1, Iowa University Press, IA, 1978.
23. G. E. P. Box and D. R. Cox, Analysis of transformations. J. R. Stat. Soc. B, 26, 211-252 (1964).
24. G. W. Snedecor and W. G. Cochran, Statistical Methods, 7th edn, Iowa University Press, IA, 1980.
25. J. Sorgel, K. G. Naber, M. Kinzig, G. Mahr and P. Muth, Comparative pharmacokinetics of ciprofloxacin and temafloxacin in humans: a review. Am. J. Med., 91 (suppl. 6A), 51S-66S (1991).
26. J. Shimada, K. Shiba, T. Oguma, H. Miwa, Y. Yoshimura, T. Nishikawa, Y. Okabayashi, T. Kitagawa and S. Yamamoto, Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob. Agents Chemother., 36, 1219-1224 (1992).
27. J. Sahai, D. P. Healy, J. Stotka and R. E. Polk, The influence of chrome administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br. J. Clin. Pharmacol., 35, 302-304 (1993).
28. M. A. Gonzalez, F. Uribe, S. D. Moisen, A. P. Fuster, A. Selen, P. G. Welling and B. Painter, Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob. Agents Chemother., 26, 741-744 (1984).
29. D. E. Nix, J. M. DeVito M. A. Whitbread and J. J. Schentag, Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. J. Antimicrob. Chemother., 19, 263-269 (1987).